BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $251,000 | -28.5% | 3,241 | -20.8% | 0.01% | -22.2% |
Q4 2021 | $351,000 | -48.5% | 4,091 | -51.8% | 0.02% | 0.0% |
Q3 2021 | $682,000 | +82.8% | 8,484 | +83.3% | 0.02% | -5.3% |
Q2 2021 | $373,000 | -4.4% | 4,629 | 0.0% | 0.02% | -13.6% |
Q1 2021 | $390,000 | +17.8% | 4,629 | +12.1% | 0.02% | +15.8% |
Q4 2020 | $331,000 | -0.3% | 4,129 | 0.0% | 0.02% | -13.6% |
Q3 2020 | $332,000 | -6.7% | 4,129 | 0.0% | 0.02% | -15.4% |
Q2 2020 | $356,000 | -4.3% | 4,129 | -9.8% | 0.03% | -21.2% |
Q1 2020 | $372,000 | -11.2% | 4,579 | -8.6% | 0.03% | +10.0% |
Q4 2019 | $419,000 | -4.3% | 5,011 | +0.0% | 0.03% | -9.1% |
Q3 2019 | $438,000 | +6.8% | 5,010 | 0.0% | 0.03% | +3.1% |
Q2 2019 | $410,000 | +0.7% | 5,010 | +0.0% | 0.03% | -3.0% |
Q1 2019 | $407,000 | +33.4% | 5,009 | +8.1% | 0.03% | +13.8% |
Q4 2018 | $305,000 | -24.5% | 4,634 | -11.6% | 0.03% | -6.5% |
Q3 2018 | $404,000 | +3.1% | 5,242 | -1.2% | 0.03% | 0.0% |
Q2 2018 | $392,000 | +10.4% | 5,307 | -2.7% | 0.03% | +6.9% |
Q1 2018 | $355,000 | -9.2% | 5,457 | -9.8% | 0.03% | -6.5% |
Q4 2017 | $391,000 | +2.9% | 6,048 | 0.0% | 0.03% | 0.0% |
Q3 2017 | $380,000 | +3.8% | 6,048 | 0.0% | 0.03% | 0.0% |
Q2 2017 | $366,000 | +19.2% | 6,048 | +2.1% | 0.03% | +14.8% |
Q1 2017 | $307,000 | +17.2% | 5,926 | +0.2% | 0.03% | +12.5% |
Q4 2016 | $262,000 | +0.4% | 5,916 | +66.0% | 0.02% | -7.7% |
Q4 2014 | $261,000 | – | 3,563 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |